Reviews/Polyphenols and Antioxidants/Vitamin E and cardiovascular events
Sup · POLY-SUP-02 · v2
Two large, carefully run trials of vitamin E pills — one in nearly 15,000 men [1] and one in over 9,500 higher-risk patients [3] — found that vitamin E did not lower the chance of heart attacks, strokes or cardiovascular death, with results sitting squarely on 'no effect'. These two studies carry most of the weight behind the claim. However, two smaller trials point the other way: one in kidney-dialysis patients [2] and one in people with proven coronary disease [4] each reported fewer cardiovascular events on vitamin E. In the coronary trial [4] the apparent benefit came almost entirely from fewer non-fatal heart attacks, while cardiovascular deaths were slightly higher, so it is not a clean win. The panel therefore accepted that vitamin E does not help the broad population but could not rule out a benefit in these specific narrow groups.
The two largest supplementation RCTs find no cardiovascular benefit: PHS II [1] (N=14,641) reports major CV events HR 1.01 (95% CI 0.90-1.13), and HOPE [3] (N=9,541) reports a primary composite RR 1.05 (95% CI 0.95-1.16), both with confidence intervals tight around the null. Against this, SPACE [2] in 196 haemodialysis patients reports a composite CV endpoint RR 0.46 (95% CI 0.27-0.78, p=0.014) and MI RR 0.3, and CHAOS [4] in 2,002 coronary patients reports a composite RR 0.53 (95% CI 0.34-0.83). The CHAOS [4] result was driven by non-fatal MI (RR 0.23) alongside a non-significant excess of cardiovascular deaths (RR 1.18, 95% CI 0.62-2.27). The null and positive trials differ sharply in population: broad or high-risk prevention [1][3] versus narrow secondary-prevention groups [2][4]. The contested point: The division is population-specific: the large trials [1][3] decisively support no effect in broad and high-risk prevention, while the smaller secondary-prevention trials [2][4] report significant benefit. Whether [4]'s composite benefit counts as real prevention is itself contested, since it rested on non-fatal MI with cardiovascular deaths numerically higher.
All 16 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Polyphenols and Antioxidants, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim is absolute ('do not prevent CV events'), but [2] SPACE and [4] CHAOS are RCTs in the corpus reporting statistically significant reductions in composite CV endpoints, directly contradicting the absolute wording in secondary-prevention populations.
The [4] CHAOS composite benefit was driven entirely by non-fatal MI (RR 0.23) while cardiovascular deaths were numerically higher (RR 1.18) — a surrogate-weighted result, not a clean hard-outcome demonstration of prevention or its absence.
Where it remains uncertain. SPACE [2] (RR 0.46) and CHAOS [4] (RR 0.53) report significant composite reductions in specific populations, and CHAOS [4]'s benefit was non-fatal-MI-driven with a non-significant excess of CV deaths (RR 1.18).
Aleatory
[2] (N=196) and [4] (events 41 vs 64) rest on small event counts, so chance plays a larger role in their point estimates.
Epistemic
The corpus tests broad/high-risk prevention [1][3] and two narrow secondary groups [2][4]; other populations are simply unobserved here.
Inferential
[4]'s composite benefit was driven by non-fatal MI (RR 0.23) while CV deaths were numerically higher (RR 1.18), so inferring hard-outcome prevention from it is unsafe.
The load-bearing papers from a corpus of 16, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Largest trial, null for major CV events — primary support for the claim
“Compared with placebo, vitamin E had no effect on the incidence of major cardiovascular events (both active and placebo vitamin E groups, 10.9 events per 1000 person-years; hazard ratio [HR], 1.01 [95% confidence interval {CI}, 0.90-1.13]; P = .86)”
Panel auditInternal validity: high · scope of inference: Middle-aged and older US male physicians initially at low cardiovascular risk.Key limitations: male physicians only · mostly low baseline risk · alternate-day dosing
Second large high-risk RCT, null (RR 1.05, 0.95-1.16) — corroborates the null
“In patients at high risk for cardiovascular events, treatment with vitamin E for a mean of 4.5 years had no apparent effect on cardiovascular outcomes.”
Panel auditInternal validity: high · scope of inference: Patients 55 or older at high cardiovascular risk (existing CVD or diabetes plus another risk factor).Key limitations: high-risk population only · 4.5-year duration may be short for prevention
Direct counter-evidence of CV-event reduction (RR 0.46) in a specific secondary-prevention population
“In haemodialysis patients with prevalent cardiovascular disease, supplementation with 800 IU/day vitamin E reduces composite cardiovascular disease endpoints and myocardial infarction.”
Panel auditInternal validity: medium · scope of inference: Haemodialysis patients aged 40-75 with pre-existing cardiovascular disease and high oxidative stress.Key limitations: small sample · narrow dialysis population · short follow-up
3 of 16 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Large well-powered trials decisively support the null, but direct in-corpus RCT counter-evidence in specific populations holds confidence below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Large hard-outcome trial in secondary-prevention coronary disease. CHAOS [4] reported a composite benefit driven by non-fatal MI with a non-significant excess of CV deaths (RR 1.18), leaving hard-outcome prevention unresolved in exactly the population where benefit appears. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An adequately powered RCT in angiographically proven coronary disease with cardiovascular death and non-fatal MI as separate pre-specified endpoints.
Open question: Does vitamin E prevent hard cardiovascular outcomes in established coronary disease, or was the CHAOS signal confined to non-fatal MI? Why it is still open: [4] shows a composite reduction driven by non-fatal MI (RR 0.23) with cardiovascular deaths numerically higher (RR 1.18, 95% CI 0.62-2.27), and no larger coronary trial in the corpus resolves this.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19